These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31290282)

  • 1. Safety of Direct-Acting Antiviral Therapy for Renal Function in Post-Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response: A Single-Center Study.
    Kawagishi N; Nakamura A; Takayama T; Haga I
    Ther Apher Dial; 2020 Apr; 24(2):184-188. PubMed ID: 31290282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
    Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
    Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
    Michels FBL; Amaral ACC; Carvalho-Filho RJ; Vieira GA; Souza ALDS; Ferraz MLG
    Arq Gastroenterol; 2020; 57(1):45-49. PubMed ID: 32294735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients.
    Friebus-Kardash J; Gäckler A; Kribben A; Witzke O; Wedemeyer H; Treckmann J; Herzer K; Eisenberger U
    Transpl Infect Dis; 2019 Oct; 21(5):e13146. PubMed ID: 31306562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
    Barrail-Tran A; Goldwirt L; Gelé T; Laforest C; Lavenu A; Danjou H; Radenne S; Leroy V; Houssel-Debry P; Duvoux C; Kamar N; De Ledinghen V; Canva V; Conti F; Durand F; D'Alteroche L; Botta-Fridlund D; Moreno C; Cagnot C; Samuel D; Fougerou-Leurent C; Pageaux GP; Duclos-Vallée JC; Taburet AM; Coilly A
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1555-1563. PubMed ID: 31384986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-Acting Antiretroviral Therapy in Renal Transplant Recipients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Report of Our Experience and Literature Review.
    Moreno-Ramirez M; Villanego F; Vigara LA; Cazorla JM; Naranjo J; Garcia T; Merino MJ; Mazuecos A
    Transplant Proc; 2020 Mar; 52(2):523-526. PubMed ID: 32035678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
    Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
    Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
    Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
    Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
    Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Chronic Hepatitis C Infection Among Egyptian Kidney Transplant Recipients: A Pilot Study.
    El Maghrabi HM; Elmowafy AY; Donia AF; Ismail MI; El-Hendy YA; Soliman R; Shiha GE; Bakr MA
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):62-67. PubMed ID: 30777525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.
    Chute DF; Chung RT; Sise ME
    Kidney Int; 2018 Mar; 93(3):560-567. PubMed ID: 29325996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.